To reliably estimate the prognoses of patients with hepatocellular carcinoma (HCC), both liver function and tumorrelated factors should be accounted for. However, there are few worldwide staging systems that assess prognostic value in the context of selecting individual patients for randomized stratification in therapeutic and clinical trials. We investigated the value of known prognostic systems and verified the usefulness of the new scoring system proposed by the Cancer of the Liver Italian Program (CLIP), as determined from 662 Japanese patients. A retrospective analysis of the HCC diagnoses at 4 Japanese institutions from 1990 and 1998 was performed. Overall survival was the only end point used in the analysis. Discriminatory ability and predictive power of the CLIP score were compared with those of Okuda stage and AJCC TNM stage. Compared with the Okuda and AJCC staging systems, the CLIP score's enhanced discriminatory capacity, which was tested by the linear trend test and Harrels' c-index, revealed a class of patients with an impressively more favorable prognosis and another class with a relatively shorter life expectancy. Moreover, the likelihood ratio test showed that the CLIP score had additional homogeneity of survival within each score above that of the Okuda stage or the AJCC stage. This was true for 3 subgroups of patients who received surgery, transcatheter arterial chemoembolizations, and percutaneous ethanol injections. Collectively, these findings indicate that the CLIP score has the highest stratification ability with regard to prognosis in patients with HCC. The CLIP score could be used internationally to stratify randomization groups in therapeutic and clinical trials. (HEPATOLOGY 2001; 34:529-534.) Hepatocellular carcinoma (HCC) is a relatively common malignant tumor worldwide, accounting for almost one million deaths annually. In the past 2 decades, some newly developed therapeutic options have been applied with varying degrees of success (i.e., liver resection and transplantation, transcatheter arterial chemoembolization [TACE], and percutaneous ethanol injection [PEI]). To reliably estimate the prognoses of patients with HCC, both liver function and tumor-related factors should be accounted for 1-3 ; however, there are few data collection systems that include both. 4 In fact, the well-known UICC and AJCC staging (TNM) criteria do not define the relative prognostic weight of variables, in terms of residual liver function. 5 Although several studies have examined predictive factors for prognosis in relation to treatment, 1,6-16 most of these have been performed in Asian institutions. Accordingly, these facilities and patient populations possess early detection plans, risk factors for primary liver cancer, a high proportion of expanding tumors, and differing rates of resectability, respectively, with regard to those in Western countries. 2, 9, 12 
Hepatocellular carcinoma (HCC) is a relatively common malignant tumor worldwide, accounting for almost one million deaths annually. In the past 2 decades, some newly developed therapeutic options have been applied with varying degrees of success (i.e., liver resection and transplantation, transcatheter arterial chemoembolization [TACE] , and percutaneous ethanol injection [PEI] ). To reliably estimate the prognoses of patients with HCC, both liver function and tumor-related factors should be accounted for [1] [2] [3] ; however, there are few data collection systems that include both. 4 In fact, the well-known UICC and AJCC staging (TNM) criteria do not define the relative prognostic weight of variables, in terms of residual liver function. 5 Although several studies have examined predictive factors for prognosis in relation to treatment, 1, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] most of these have been performed in Asian institutions. Accordingly, these facilities and patient populations possess early detection plans, risk factors for primary liver cancer, a high proportion of expanding tumors, and differing rates of resectability, respectively, with regard to those in Western countries. 2, 9, 12 In addition, many of these studies included patients from different institutions that did not necessarily have the same diagnostic or therapeutic work-up or studied patients submitted to only 1 treatment modality. Thus, there is a need for a simple worldwide staging system that assesses prognostic value and may help in the selection of individual patients to better stratify randomization in therapeutic and clinical trials.
The Cancer of the Liver Italian Program (CLIP) proposed a new scoring system (CLIP score) that accounts for both liver function and tumor characteristics relevant to prognostic assessment for patients with HCC in 1998. 17, 18 The CLIP score consisted of 4 variables: Child-Pugh stage, tumor morphology, ␣-fetoprotein (AFP), and portal vein invasion. Thus, this score is easy to calculate and is based on variables that are routinely assessed during clinical examination, biochemical staging, and ultrasound studies of the liver. However, the question we have to ask here is whether the CLIP score will be validated despite differences in races (western vs. eastern), etiologies of HCC, or the rate of therapeutic modalities such as liver resection.
The Kagoshima Liver Cancer Study Group was settled in 1990, with the aim of performing prospective, therapeutic trials and studies regarding diagnostic and prognostic assessments of HCC. 19 The purpose of this study is to verify the value of known prognostic systems and to explore whether it is possible to use the CLIP score in 662 Japanese HCC patients, including 143 patients undergoing surgery.
patient, data and modality of HCC diagnosis, data of death or latest information regarding vital status, presence of cirrhosis (diagnosed with previous liver biopsy or unequivocal laboratory and imaging signs), Child-Pugh class 20 and its constitutive variables (albumin, bilirubin, prothrombin time, ascites, encephalopathy), tumor type, tumor extension, portal vein thrombosis, AFP level (ng/mL) at diagnosis, evidence of distant metastasis at diagnosis, locoregional treatment and, systemic treatment. The quality control of data was made by verifying consistency (e.g., claimed categories of established staging systems were matched with reported values of constituting variables) and possible input errors, as all data entered were checked by 2 operators. When inconsistencies were found, they were discussed with the single investigator.
Statistical Methods. Overall survival was the only end point used in the analysis. Survival was defined as the time elapsed from the date of diagnosis to either the date of death or the date of last follow-up information. Univariate survival curves were estimated using the Kaplan-Meier method and were compared by means of the log rank test.
By using survival time as an outcome measure, important criteria for assessing the performance of any prognostic system were the following: (1) The difference in survival time is small among patients classified into the same group by that system (homogeneity). (2) As compared with this difference, there are much greater differences in the survival times among patients classified into different groups (discriminatory ability). (3) The mean survival time for a group classified as favorable by that system is always longer than the survival times noted in less favorable groups (monotonicity of gradients). To compare the performance of the 3 prognostic systems, the linear trend 2 test 21 (which is more suitable than the log-rank test for measuring both the discriminatory power and monotonicity of the gradient across categories) and the likelihood ratio (LR) test for measuring homogeneity were used. In the LR test, we used the ordinary prognostic score rather than transforming it into dummy variables; thus, the LR test can also estimate the monotonicity of gradient. In both tests, the degree of freedom is always one so that 2 prognostic systems with different numbers of categories can be compared. These tests are based on the proportional hazards model. Harrels' c-index, 22 which requires no assumption of the model, was also calculated to verify the discriminatory ability of each staging system. Briefly, this index represents the proportion of correct predictions or concordance in all possible pairs of patients. Suppose that, in a given pair, patient A has a worse prognostic score than patient B. If the survival time of A is shorter (longer) than that of B, the prediction is concordant (discordant) with the actual outcome. If, on the other hand, one patient is censored earlier than the time of death or census for the other patient, that pair is not counted. We also performed separate analysis for subgroups of patients who received surgery, TACE, or PEI. All analyses except c-index (calculated by an original program) were performed with the StatView statistical software (Version 5.0, SAS Institute, Cary, NC) and/or the SPSS Medical Pack for Windows (Version 10.0, SPSS, Inc., Chicago, IL). Table 2 shows the characteristics of the 662 patients collected from 4 institutions. The patients were predominantly men (male/female ratio 3:1), and the median age was 63 years. As of January 31, 1999, 440 patients (66.4%) had died (5 patients were lost to follow-up). Overall median survival was 37.7 months. Liver function and tumor variables that consist of the 3 prognostic systems were significantly associated with survival as shown by the median survival time: all variables' P values were Ͻ .0001 by the log rank test (Table 3) . At our centers, treatment choice strongly depends on the liver function reserve and tumor extension ( Fig. 1 ), such that a retrospective comparison of treated and untreated patients is accordingly biased. As shown in Table 4 , 91.6% of patients receiving surgery and 93.2% receiving PEI were categorized in CLIP score 0 and score 2 (better), respectively, although 41.8% receiving TACE had CLIP scores greater than 3 (worse). In the Okuda staging, this tendency was similar. However, the number of categories seemed to be too few to Fig. 2 , to compare the relative use in prognostic stratification between the CLIP score and the other 2 criteria, the survival curves are displayed. The CLIP score performs better than the other systems, allowing an improved characterization of the extreme categories and of patients with the intermediate Okuda stage. As shown in Table 5 , this was also confirmed by the linear trend test: the highest 2 (238.96) of the CLIP score. In addition, the independent homogenizing ability and stratification value of the CLIP score, the Okuda stage, and the AJCC stage were investigated by means of the LR test within a Cox's proportional-hazard regression model and c-index. The CLIP score showed a much higher 2 (184.344) compared with those in the other 2 systems. This was true for the whole group of patients and the subgroups of patients undergoing surgery, PEI, and TACE. The c-index was also higher in the CLIP score than in the Okuda and AJCC staging systems. This was also consistent with the subgroups of patients undergoing surgery or PEI; however, the CLIP score was the second highest after the Okuda stage only in patients receiving TACE. Compared with the Okuda stage, the AJCC stage simply showed a predictive efficacy for patients receiving surgery.
RESULTS

DISCUSSION
Staging criteria for HCC have been developed, but are not yet fully integrated into clinical practice, because they do not necessarily reflect prognostic significance (even in patients undergoing surgery). [23] [24] [25] [26] Furthermore, so many factors affect the prognosis of patients with HCC, 1, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] that it is still difficult to design well-controlled clinical trials to assess new experimental modes of therapy.
This study revealed that the new prognostic system proposed by CLIP in a western country also has independent prognostic value equal to (if not greater than) that of the Okuda and AJCC staging systems even in a series of 662 Japanese patients with HCC. The CLIP system's ability to allow accurate prognostic stratification (by the linear trend test and by c-index) and homogeneity (by the LR test) was the highest among the 3 prognostic systems. This was true in the 3 subgroups of patients undergoing surgery, PEI, and TACE. Although very few patients undergoing surgery (2%) were concerned with the original study reported by the CLIP, our results included 143 surgical patients (22%) and also showed that the CLIP score could offer better prognostic information than the other staging systems. According to the c-index, the CLIP score was second highest to the Okuda stage only in patients receiving TACE, as all other statistics showed that the CLIP score was best. As stated before (see Fig. 1 and Table 4 ), most patients who underwent TACE had similar types of HCC: multiple nodular HCCs without major vascular invasion. In such cases, it is possible that the discriminative efficacy of a given scoring system may be more reflected by liver function rather than by tumor extension itself. Compared with the CLIP score, the Okuda stage implies high points regarding liver function, such that the Okuda might show better discriminatory ability than that of the CLIP score here. After this report was submitted for publication, Fariati et al. 27 in Italy reported a validation study of the CLIP, Okuda, and TNM staging systems and pointed out that the CLIP score can identify patients with different prognoses, particularly in the early phases of HCC. Overall, we emphasize that the CLIP score has greater predictive value for patients with every type of treatment. Better performance of the CLIP score as compared with the Okuda stage is a result of the inclusion of tumor type, portal vein thrombosis, and AFP level. 17 Moreover, the present findings that the AJCC staging system were unsatisfactory compared with the CLIP staging systems, confirm previous observations that incorporating some measure of liver function into the clinical cancer staging system is essential for both utility and widespread use. 10, 14, 28 Because it was expected that the CLIP score worked better than the Okuda and AJCC staging systems just because of the higher number of categories, we calculated the Akaike information criterion (AIC) values that penalize for the number of parameters of the model (data not shown). 29 However, the evidence for supporting the superiority of the Okuda and AJCC staging systems was exiguous: the AIC values in each model were almost the same. Conversely, for a prognostic system with a greater number of groups or categories, it is more difficult to satisfy the monotonicity of gradients although each group is more homogenous. The CLIP score also overcomes this weakness, as shown by the results of the linear trend test: the highest 2 (238.96) of the CLIP score. CLIP investigators worried about very similar behavior of survival curves for CLIP score 2 and 3 categories in their validation analysis. 18 Our study, however, verifies that there is a clear difference between the 2 scores (median survival times: 26.4 and 14.1 months, respectively). Strictly speaking, predictive accuracy referring to the reliability of prediction, the concordance between predicted and observed outcomes, may be considered. However, predictive powers of a given indicator are not necessarily universal among the available treatment strategies or among countries because of racial differences and medical level. Thus, the discrimination ability and the homogeneity of the CLIP score should be emphasized again for the purpose of stratifying patients within therapeutic trials, thereby reducing the overly optimistic results caused by patient selection, on one side, and the large heterogeneity among studies, on the other side. Precise tumor size is a point of debate in terms of efficacy and priority of each treatment modality. 10, 30, 31 Akriviadis et al. 31 reported that PEI may be as effective as surgical resection for small HCC lesions (i.e., those less than 3 cm in diameter) and, in general, should be applied to lesions smaller than 5 cm in diameter, alone or in combination with TACE. However, in our surgery group, the patients in pathologic TNM stage I, who had strict T categories such as Յ2 cm in diameter, did not have significantly better prognoses than those in stage II (data not shown). There still may be room for the argument favoring the inclusion of tumor size. The tumor morphology in the CLIP score, however, may implicate tumor size to some extent, because patients with the tumor extension Յ50% was strictly correlated with the tumor size Յ5 cm (P Ͻ .0001, 399 patients showed both) in our study.
In terms of the severity of liver disease, Japanese physicians have been familiar with the clinical stage 32 more than the Child-Pugh stage. In our series, no clear differences were found in the median survival period of each CLIP score when using the former categories instead of the latter one. This information may be of value for retrospective data collection regarding Japanese patients. Moreover, a comparison with other groups of patients with other causes of liver disease such as metabolic disease would be of interest. It also must be noted that the histologic status of the noncancerous regions of the liver influence tumor recurrence, especially secondary growths of HCC. 30, [33] [34] [35] Interestingly, 2 recent articles dealing with the prognosis of patients with HCC have been correlated with physical parameters such as performance status and the presence or absence of symptoms. 36, 37 However, we did not compare those classifications in this study, because the physical parameters would have been difficult to determine and organize retrospectively. The CLIP group also pointed out that no quantitative assessment of the predictive value of those 2 systems was reported. 18 All scoring systems arise as a compromise between simplicity and discriminatory ability. 15 Thus, we believe that the CLIP score increases predictive efficacy, while remaining simple compared with the Okuda system. Moreover, a previous report analyzing 412 cases in the United States emphasized that efficacy studies regarding therapeutic procedures or adjuvant therapies should stratify patients according to vascular invasion, size of tumors, AFP levels, and the presence or absence of cirrhosis. 10 Interestingly, these 4 categories are almost the same as those in the CLIP scoring system. Thus, we are confident that the CLIP scoring system would serve well NOTE. Regarding the discriminatory ability, the homogeneity, and the monotonicity of gradients, the model with the highest 2 by the linear trend test and the LR test was considered as the best model. Furthermore, the discriminatory ability of each model was verified by Harrels' c-index. HEPATOLOGY Vol. 34, No. 3, 2001 for widespread use in the selection of patients for prospective trials. Given the aforementioned results and suggestive findings, it can be concluded that the CLIP scoring system for HCC patients possesses utility, stratification value, and widespread use. The study concerning accurate pathologic tumor classification and staging remains to be completed for future investigation and discussion.
